Evidence map›Paper›PMID 31910445›Full record

ArticlePloS one2020

Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015.

Richard Makurumidze, Tsitsi Mutasa-Apollo, Tom Decroo, Regis C Choto, Kudakwashe C Takarinda, Janet Dzangare, Lutgarde Lynen, Wim Van Damme, James Hakim, Tapuwa Magure and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
0.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. HIV Viral Re-Suppression on Second-Line ART in Southern Zimbabwe.International journal of environmental research and public health · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Richard MakurumidzeCollege of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID 0000-0001-6490-1818
Tsitsi Mutasa-ApolloAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Tom DecrooInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-1205-1484
Regis C ChotoAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Kudakwashe C TakarindaAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Janet DzangareAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Lutgarde LynenInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-7183-4895
Wim Van DammeInstitute of Tropical Medicine, Antwerp, Belgium.
James HakimCollege of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Tapuwa MagureNational AIDS Council, Harare, Zimbabwe.
Owen MugurungiAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Simbarashe RusakanikoCollege of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Ministry of Health and Child Welfare · ZWUniversity of Zimbabwe · ZWInstituut voor Tropische Geneeskunde · BENational AIDS Council · ZWResearch Foundation - Flanders · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe last evaluation to assess outcomes for patients receiving antiretroviral therapy (ART) through the Zimbabwe public sector was conducted in 2011, covering the 2007-2010 cohorts. The reported retention at 6, 12, 24 and 36 months were 90.7%, 78.1%, 68.8% and 64.4%, respectively. We report findings of a follow-up evaluation for the 2012-2015 cohorts to assess the implementation and impact of recommendations from this prior evaluation.

methodsA nationwide retrospective study was conducted in 2016. Multi-stage proportional sampling was used to select health facilities and study participants records. The data extracted from patient manual records included demographic, baseline clinical characteristics and patient outcomes (active on treatment, died, transferred out, stopped ART and lost to follow-up (LTFU)) at 6, 12, 24 and 36 months. The data were analysed using Stata/IC 14.2. Retention was estimated using survival analysis. The predictors associated with attrition were determined using a multivariate Cox regression model.

resultsA total of 3,810 participants were recruited in the study. The median age in years was 35 (IQR: 28-42). Overall, retention increased to 92.4% (p-value = 0.060), 86.5% (p-value<0.001), 79.2% (p-value<0.001) and 74.4% (p-value<0.001) at 6, 12, 24 and 36 months respectively. LTFU accounted for 98% of attrition. Being an adolescent or a young adult (15-24 years) (vs adult;1.41; 95% CI:1.14-1.74), children (<15years) (vs adults; aHR 0.64; 95% CI:0.46-0.91), receiving care at primary health care facility (vs central and provincial facility; aHR 1.23; 95% CI:1.01-1.49), having initiated ART between 2014-2015 (vs 2012-2013; aHR1.45; 95%CI:1.24-1.69), having WHO Stage IV (vs Stage I-III; aHR2.06; 95%CI:1.51-2.81) and impaired functional status (vs normal status; aHR1.25; 95%CI:1.04-1.49) predicted attrition.

conclusionThe overall retention was higher in comparison to the previous 2007-2010 evaluation. Further studies to understand why attrition was found to be higher at primary health care facilities are warranted. Implementation of strategies for managing patients with advanced HIV disease, differentiated care for adolescents and young adults and tracking of LTFU clients should be prioritised to further improve retention.

Indexed as

AdolescentAdultAnti-HIV AgentsAnti-Retroviral AgentsChildChild, PreschoolFemaleHIV InfectionsHumansInfantInfant, NewbornMaleMedication AdherenceMiddle AgedRetrospective StudiesSurvival AnalysisAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID31910445
PMCPMC6946589
OpenAlexW3000338246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.